

UNIQUE CLINICIAN NUMBER

--	--	--	--



**Peter Mac**

Peter MacCallum Cancer Centre  
Victoria Australia

## Translating Evidence into Practice:

Optimising and Facilitating Prevention and Screening  
in Women with a Strong Family History of Breast Cancer

**1.** Do you consent to participating in this research?

Yes

**2.** What is your gender?

Male

Female

Other

**3.** What is your age?

20 – 29

30 – 39

40 – 49

50 – 59

60+

**OR**  I would rather not say

**4.** What percentage of your time is spent in the following practice types? Please ensure percentages equal 100%.

--	--	--

 % public

--	--	--

 % private

**5.** What is your profession?

GP

Breast Surgeon

General Surgeon

Gynaecologist

Gynaecological Oncologist

## RISK-REDUCING MEDICATIONS

6. Before this study, had you ever heard of breast cancer risk-reducing medications/chemoprevention? These can be prescribed to women without breast cancer.

Yes

No → **Please skip to the last page and enter your details for your chance to win an Apple Ipad.**

### Definition of risk-reducing medications

Medications that reduce the risk of breast cancer may be considered by women who don't have breast cancer but are at an increased risk. These medicines are also known as chemoprevention. The most common risk-reducing medication is tamoxifen. Other risk-reducing medications include raloxifene, anastrozole and exemestane. These tablets are taken once a day, usually for five years.

7. Have you ever discussed risk-reducing medications with your patients and/or prescribed them to your patients? **Tick all that apply.**

I have initiated discussion with patients

Patients have initiated discussion with me

I have written first prescription

I have written ongoing prescriptions

I have never discussed or prescribed risk-reducing medications with patients

8. How confident are you in providing advice/information to patients about risk-reducing medications?

Very confident

Somewhat confident

Not too confident → **please answer Question 8a**

Not at all confident → **please answer Question 8a**

Unsure

8a. If you answered 'Not too confident' or 'Not at all confident' at Q8, why are you not confident providing this advice/information to patients?


**9.** Thinking about discussing or prescribing risk-reducing medications with your patients, how much of a barrier are each of the following?

	<b>Strong barrier</b>	<b>Somewhat a barrier</b>	<b>Not at all a barrier</b>	<b>Not applicable</b>
1. I have insufficient knowledge of risk-reducing medications	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
2. It is difficult to measure whether the medication is working	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
3. I find it hard to access tools/resources to help <u>me</u> estimate patients' breast cancer risk	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
4. I find it hard to access good information/resources for <u>my patients</u> e.g. patient information sheets	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
5. There is no evidence that they reduce mortality	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

	<b>Strong barrier</b>	<b>Somewhat a barrier</b>	<b>Not at all a barrier</b>	<b>Not applicable</b>
6. I have difficulty identifying patients suitable for risk-reducing medication	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
7. I have inadequate training and confidence in breast cancer risk assessment	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
8. I have difficulty explaining to patients the pros and cons of risk-reducing medications	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
9. I am not confident in providing advice/information to patients about risk-reducing medications	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

	<b>Strong barrier</b>	<b>Somewhat a barrier</b>	<b>Not at all a barrier</b>	<b>Not applicable</b>
10. It is not my role to discuss risk-reducing medications	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
11. There are no incentives/rewards for discussing risk-reducing medications with patients	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
12. Lack of time during consultations	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
13. There are no procedures (e.g. a checklist that facilitates discussion) that encourage me to discuss risk-reducing medications	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

- continued on page 4 -

	Strong barrier	Somewhat a barrier	Not at all a barrier	Not applicable
14. Medication side effects	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
15. I don't believe they decrease the risk of breast cancer	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
16. I'm concerned I might increase the patient's worry about breast cancer	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
17. I don't think patients want to discuss taking medications for prevention of breast cancer	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
18. I feel uncomfortable prescribing a 'cancer drug' to healthy women	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

	Strong barrier	Somewhat a barrier	Not at all a barrier	Not applicable
19. Patients don't ask me about risk-reducing medications	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
20. I don't routinely assess breast cancer risk with my patients	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
21. There are other things I wish to achieve in most consultations that interfere with my ability to discuss risk-reducing medications	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
22. I forget to discuss risk-reducing medications with patients	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

**9a.** Which one of these factors (1 to 22) is the greatest barrier?

**9b.** Are there any other barriers that discourage you from discussing or prescribing risk-reducing medications with patients? If no, please leave blank.


**10.** Thinking about discussing or prescribing risk-reducing medications with your patients, how much of a facilitator are each of the following?

	Strong facilitator	Somewhat a facilitator	Not at all a facilitator	Not applicable
1. If the patient is diagnosed with <u>atypical hyperplasia</u> that increases their risk of breast cancer	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
2. If the patient is diagnosed with <u>lobular carcinoma in situ (LCIS)</u> that increases their risk of breast cancer	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
3. If a patient has a strong family history of breast cancer	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
4. The beneficial effects of risk-reducing medications e.g. better blood lipid profile and improvements in bone density with tamoxifen	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
5. If I had better tools to help me identify patients who were suitable	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
6. Knowing some risk-reducing medications are PBS funded	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
7. Sometimes it is easier to discuss risk-reducing medications than bilateral mastectomy	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
8. Support from my peers	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
9. Support from specialists	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
10. Clear guidelines/recommendations e.g. RACGP and Cancer Australia guidelines	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
11. If it were endorsed as part of my professional role by the relevant college or other peak body	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
12. If my medical software prompted me to discuss risk-reducing medications	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
13. If I knew my colleagues discuss it with their patients	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
14. I expect positive outcomes for women who take risk-reducing medications	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

**10a.** Which one of these factors (1 – 14) is the greatest facilitator?

**10b.** Are there any other facilitators that encourage you to discuss risk-reducing medications with patients? If no, please leave blank.


**11.** What do you think should be the role of each clinician type below with regard to discussing and prescribing risk-reducing medications. **Tick all that apply.**

Clinician type	Initiate discussion of risk-reducing medications	Write first prescription	Write ongoing prescriptions
11a. GP role:	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
11b. Breast/General Surgeon role:	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
11c. Familial Cancer Clinic/Genetic Specialist role:	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>


**12.** In which of these circumstances do you think it is appropriate to discuss risk-reducing medications? **Tick all that apply.**

- In a consultation where breast cancer risk happens to come up.
- During a consultation specifically planned to focus on breast cancer risk.
- During a consultation focused on general preventive healthcare.
- There is no circumstance under which I would discuss risk-reducing medications.

**13.** Have you heard of iPrevent, a web-based tool to help clinicians and patients collaboratively assess and manage breast cancer risk? ([www.petermac.org/iprevent](http://www.petermac.org/iprevent))

- Yes
- No

**Please enter your details on the last page for your chance to win an Apple iPad.**



**THIS PAGE IS INTENTIONALLY BLANK**



**Peter Mac**

Peter MacCallum Cancer Centre  
Victoria Australia

## Thank you for completing the survey.

For your chance to win an Apple iPad please provide your email address:

Please return completed survey in the reply paid envelope.